EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States

Bijal Shah iD, Mei Xue iD, Wesley Furnback, Kaitlyn Esselman iD, Po-Ya Chuang iD, Keri Yang

Hematological Oncology · 2026-05 · 44 (3)

DOI: 10.1002/hon.70201 ↗

At a glance

Journal article in Hematological Oncology, published online on 2026-05-23. Written by Bijal Shah and 5 co-authors. Institution: Moffitt Cancer Center, Tampa, Florida, USA. Major MEDLINE topics: Lymphoma, Mantle-Cell, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Patient Acceptance of Health Care. 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: BeOne Medicines Ltd.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The introduction of Bruton tyrosine kinase inhibitors (BTKis) to the mantle cell lymphoma (MCL) treatment paradigm has shown promising results for patient outcomes. However, insufficient real‐world evidence remains to compare the outcomes of different BTKi treatments in MCL. This study aimed to analyze BTKi utilization and differences in patient characteristics, treatment outcomes, and healthcare resource utilization among patients with MCL during their first use of BTKi therapy. A retrospective study was conducted using Symphony Integrated Dataverse (IDV), which is a longitudinal, de‐identified U.S. healthcare claims database. The study included patients with MCL with their first BTKi administered as monotherapy or in combination with other agents between 1/1/2020 and 12/31/2022. Patients were followed at least 90 days after BTKi initiation until the end of the study period or until lost to follow‐up (3/31/2023). Patient demographics and clinical characteristics were measured at baseline. Time to discontinuation, treatment duration, switching, compliance, and healthcare resource utilization (per patient per month [PPPM]) were measured during the follow‐up period. A total of 1458 patients initiating their first BTKi were included in the study: 667 in the acalabrutinib group, 509 in the ibrutinib group, and 282 in the zanubrutinib group. Switching rates within 90 days were lowest for the zanubrutinib group (0.71%), followed by the acalabrutinib group (1.8%) and then the ibrutinib group (2.16%). The median time to discontinuation was longest for the zanubrutinib group (188.5 days) compared to the acalabrutinib group (179 days) and the ibrutinib group (161.5 days). Compliance at 360 days was significantly different across the BTKis, highest for the zanubrutinib group (16.9%), followed by the acalabrutinib group (13.2%) and the ibrutinib group (10.8%). The zanubrutinib group had numerically lower mean PPPM outpatient visits and inpatient services than the acalabrutinib and ibrutinib groups. This real‐world study suggested that the zanubrutinib group demonstrated lower switching rates, longer time to discontinuation, improved compliance, and less healthcare resource use compared to the acalabrutinib and ibrutinib groups in patients with MCL.

Subjects

MeSH terms (MEDLINE)

Lymphoma, Mantle-CellAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPatient Acceptance of Health CareHumansFemaleRetrospective StudiesMaleUnited StatesAgedMiddle AgedPiperidinesAged, 80 and overAdenineBenzamides

Author keywords

administrative claimseconomicslymphomamolecular targeted therapynon‐hodgkinpharmaceuticalretrospective study

Substances

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPiperidinesBTK protein, humanibrutinibAdenineBenzamides

Authors and institutions

  • Moffitt Cancer Center, Tampa, Florida, USA.
  • BeOne Medicines Ltd, San Carlos, California, USA.
  • Real Chemistry, Inc., New York, New York, USA.

ORCID profiles: Bijal Shah, Mei Xue, Kaitlyn Esselman, Po-Ya Chuang

Funding

  • BeOne Medicines Ltd

Cite

APA

Shah, B., Xue, M., Furnback, W., Esselman, K., Chuang, P. Y., & Yang, K. (2026). Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States. Hematological Oncology, 44(3). https://doi.org/10.1002/hon.70201

Vancouver

Shah B, Xue M, Furnback W, Esselman K, Chuang PY, Yang K. Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States. Hematological Oncology. 2026;44(3). doi:10.1002/hon.70201

BibTeX
@article{Shah2026,
  author = {Shah, Bijal and Xue, Mei and Furnback, Wesley and Esselman, Kaitlyn and Chuang, Po-Ya and Yang, Keri},
  title = {Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {3},
  doi = {10.1002/hon.70201}
}
Start for free →